Amicus Therapeutics, Inc. (FOLD)

Market Cap	3.07B
Revenue (ttm)	399.36M
Net Income (ttm)	-151.58M
Shares Out	295.38M
EPS (ttm)	-0.51
PE Ratio	n/a
Forward PE	1,518.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	92,702
Open	10.27
Previous Close	10.33
Day's Range	10.27 - 10.40
52-Week Range	9.70 - 14.57
Beta	0.76
Analysts	Buy
Price Target	19.00 (+82.69%)
Earnings Date	May 8, 2024

About FOLD

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and Glaxo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 31, 2007
• Employees: 517
• Stock Exchange: NASDAQ
• Ticker Symbol: FOLD

Financial Performance

In 2023, FOLD's revenue was $399.36 million, an increase of 21.30% compared to the previous year's $329.23 million. Losses were -$151.58 million, -35.92% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for FOLD stock is "Buy." The 12-month stock price forecast is $19.0, which is an increase of 82.69% from the latest price.

Price Target

$19.0

(82.69% upside)

Analyst Consensus: Buy